GSA Capital Partners LLP Invests $944,000 in BioMarin Pharmaceutical Inc. $BMRN

Key Points

• GSA Capital Partners initiated a $944,000 position in BioMarin Pharmaceutical by purchasing 16,501 shares. Institutional investors collectively own 98.71% of the company.
• Analyst sentiment remains generally positive, with BioMarin receiving a “Moderate Buy” consensus rating and an average price target of $88.41, although some analysts maintain neutral ratings.
• BioMarin reported quarterly revenue of $989.71 million, up 20% year over year, and adjusted EPS of $1.20, exceeding analyst expectations. The company also raised its 2026 outlook and agreed to acquire Alesta Therapeutics for $275 million upfront.

GSA Capital Partners LLP bought a new stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 16,501 shares of the biotechnology company's stock, valued at approximately $944,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Swedbank AB lifted its stake in shares of BioMarin Pharmaceutical by 70.6% during the fourth quarter. Swedbank AB now owns 796,737 shares of the biotechnology company's stock worth $47,350,000 after purchasing an additional 329,794 shares in the last quarter. LSV Asset Management grew its stake in shares of BioMarin Pharmaceutical by 4.3% in the fourth quarter. LSV Asset Management now owns 882,200 shares of the biotechnology company's stock valued at $52,429,000 after buying an additional 36,700 shares in the last quarter. C WorldWide Group Holding A S raised its holdings in shares of BioMarin Pharmaceutical by 12.6% during the 4th quarter. C WorldWide Group Holding A S now owns 267,851 shares of the biotechnology company's stock valued at $15,918,000 after buying an additional 30,000 shares during the period. Horizon Investments LLC raised its holdings in shares of BioMarin Pharmaceutical by 22.3% during the 4th quarter. Horizon Investments LLC now owns 99,681 shares of the biotechnology company's stock valued at $5,924,000 after buying an additional 18,143 shares during the period. Finally, Fideuram Intesa Sanpaolo Private Banking S.P.A. acquired a new position in BioMarin Pharmaceutical during the 4th quarter worth approximately $1,901,000. Institutional investors and hedge funds own 98.71% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on BMRN shares. Oppenheimer upped their price target on BioMarin Pharmaceutical from $95.00 to $97.00 and gave the stock an "outperform" rating in a report on Friday, August 7th. The Goldman Sachs Group assumed coverage on shares of BioMarin Pharmaceutical in a research note on Monday, May 11th. They set a "neutral" rating and a $69.00 price objective on the stock. Citigroup boosted their target price on shares of BioMarin Pharmaceutical from $75.00 to $76.00 and gave the stock a "buy" rating in a research report on Thursday, July 16th. Wall Street Zen upgraded shares of BioMarin Pharmaceutical from a "hold" rating to a "buy" rating in a research note on Saturday, August 8th. Finally, UBS Group reaffirmed a "neutral" rating on shares of BioMarin Pharmaceutical in a report on Tuesday, July 14th. One analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $88.41.

More BioMarin Pharmaceutical News

Here are the key news stories impacting BioMarin Pharmaceutical this week:

• Positive Sentiment: BioMarin agreed to acquire Alesta Therapeutics for $275 million upfront, plus potential development and regulatory milestone payments. The deal gives BioMarin ALE1, a clinical-stage program that could become the first oral treatment for hypophosphatasia, a rare skeletal disease with significant unmet need. The asset could broaden BioMarin’s rare-disease pipeline and expand its exposure to larger patient markets. BioMarin to Acquire Alesta Therapeutics
• Positive Sentiment: Wedbush said the Alesta transaction strengthens BioMarin’s long-term growth outlook, reinforcing the view that ALE1 could provide a strategically attractive growth opportunity beyond the company’s existing commercial portfolio. BioMarin Pharmaceutical's Alesta Deal Strengthens Long-Term Growth Outlook
• Positive Sentiment: Piper Sandler raised its BioMarin price target to $88 from $82 and maintained an overweight rating. Barclays also lifted its target to $111 from $105 and retained an overweight rating, reflecting substantial expected upside based on their models.
• Neutral Sentiment: HC Wainwright lowered its price target to $59 from $60 and assigned a neutral rating. The revised target implies downside from the current trading level, highlighting that some analysts view the shares as fully valued despite the pipeline opportunity.
• Neutral Sentiment: Recent coverage has also focused on BioMarin’s raised 2026 outlook and an ESOP shelf offering. The outlook may support investor confidence, while the offering introduces a potential capital-structure consideration that investors will monitor.

BioMarin Pharmaceutical Trading Up 0.5%

Shares of BMRN opened at $66.99 on Wednesday. BioMarin Pharmaceutical Inc. has a one year low of $49.26 and a one year high of $70.98. The stock has a 50-day moving average price of $59.94 and a 200 day moving average price of $57.65. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.32 and a current ratio of 2.39. The company has a market capitalization of $12.97 billion, a P/E ratio of 181.05, a P/E/G ratio of 0.47 and a beta of 0.24.

BioMarin Pharmaceutical (NASDAQ:BMRN - Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The biotechnology company reported $1.20 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.95 by $0.25. BioMarin Pharmaceutical had a return on equity of 5.32% and a net margin of 2.14%.The company had revenue of $989.71 million for the quarter, compared to the consensus estimate of $932.03 million. During the same period in the previous year, the business earned $1.44 EPS. BioMarin Pharmaceutical's revenue for the quarter was up 20.0% compared to the same quarter last year. BioMarin Pharmaceutical has set its FY 2026 guidance at 4.900-5.100 EPS. Sell-side analysts forecast that BioMarin Pharmaceutical Inc. will post 4.12 EPS for the current fiscal year.

BioMarin Pharmaceutical Profile

BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.

The company's commercial portfolio includes several approved therapies targeting inherited disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source